New combo therapy aims to boost red blood cells in bone marrow disorder
NCT ID NCT07463820
First seen Mar 18, 2026 · Last updated May 13, 2026 · Updated 8 times
Summary
This study tests whether adding epoetin alfa or emavusertib to luspatercept improves red blood cell counts better than luspatercept alone in 270 adults with low-risk myelodysplastic syndrome and anemia. Participants will receive one of three treatment combinations. The goal is to reduce or eliminate the need for blood transfusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.